Accessibility Menu
Relmada Therapeutics Stock Quote

Relmada Therapeutics (NASDAQ: RLMD)

$2.14
(-4.5%)
-0.10
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$2.14
Daily Change
(-4.5%) $0.10
Day's Range
$1.98 - $2.26
Previous Close
$2.14
Open
$2.26
Beta
-0.03
Volume
166,970
Average Volume
741,352
Market Cap
71M
Market Cap / Employee
$2.14M
52wk Range
$0.24 - $3.98
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$2.21
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Relmada Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
RLMD-41.21%-93.58%-42.26%-96%
S&P+14.5%+93.32%+14.09%+241%

Relmada Therapeutics Company Info

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit$0.00M0.0%
Market Cap$19.92M-78.0%
Market Cap / Employee$1.17M0.0%
Employees17-15.0%
Net Income-$9.87M44.5%
EBITDA-$10.22M45.7%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$1.35M-35.1%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.00M0.0%
Short Term Debt$0.00M0.0%

Ratios

Q2 2025YOY Change
Return On Assets-147.18%-57.3%
Return On Invested Capital-113.88%-27.8%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$6.40M51.7%
Operating Free Cash Flow-$6.40M51.7%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book1.590.330.230.89-29.33%
Price to Tangible Book Value1.590.330.230.89-29.33%
Enterprise Value to EBITDA-1.901.531.030.07-106.37%
Return on Equity-116.6%-132.3%-160.3%-175.1%74.42%
Total Debt$0.00M$0.00M$0.00M$0.00M-

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.